SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris reported its 2025 financial results and provided updates on…

Pharvaris N.V. · 6-K filed Apr 2, 2026 at 06:50 ET

At the news

MIXEDIMPACT 6/10

6-K filed Apr 2, 2026 at 06:50 ET

Pharvaris reported its 2025 financial results and provided updates on its clinical development pipeline. Key developments include completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR with topline data expected in Q3 2026, continued progress on the NDA submission for deucrictibant IR in 1H 2026, and ongoing enrollment in the CREAATE study for AAE-C1INH. The company reported €291.7 million in cash as of December 31, 2025, with full-year R&D expenses increasing to €124.5 million.

  • Enrollment completed in CHAPTER-3 pivotal study for deucrictibant XR; topline data expected in Q3 2026
  • NDA submission for deucrictibant IR remains on track for 1H 2026
  • Enrollment ongoing in CREAATE pivotal study for AAE-C1INH
  • Cash and cash equivalents of €291.7 million as of December 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access